Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totaling 228,199 shares, a decline of 42.8% from the August 31st total of 398,714 shares. Based on an average trading volume of 934,294 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.7% of the shares of the company are short sold.

Catheter Precision Stock Up 4.9%

Shares of Catheter Precision stock traded up $0.01 during trading hours on Wednesday, hitting $0.15. The company had a trading volume of 838,612 shares, compared to its average volume of 1,541,009. Catheter Precision has a twelve month low of $0.13 and a twelve month high of $3.20. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.19 and a quick ratio of 0.18. The company’s 50-day moving average is $0.22 and its two-hundred day moving average is $0.69. The company has a market cap of $2.16 million, a P/E ratio of -0.02 and a beta of -1.03.

Shares of Catheter Precision are set to reverse split before the market opens on Monday, October 5th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 4th.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping the consensus estimate of ($19.00) by $18.08. The company had revenue of $1.02 million for the quarter, compared to the consensus estimate of $2.00 million. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.

About Catheter Precision

Catheter Precision, Inc is a medical device company focused on developing technologies for electrophysiology procedures used to diagnose and treat cardiac arrhythmias. Its products are designed to support physicians during catheter-based cardiac procedures, particularly those involving ventricular arrhythmias.

The company’s portfolio includes the VIVO system, a noninvasive cardiac mapping platform intended to help physicians identify the origin of ventricular arrhythmias and plan catheter ablation procedures.